A detailed history of Edge Rock Capital LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Edge Rock Capital LLC holds 1,804 shares of ABBV stock, worth $316,746. This represents 0.26% of its overall portfolio holdings.

Number of Shares
1,804
Previous 1,716 5.13%
Holding current value
$316,746
Previous $294,000 21.09%
% of portfolio
0.26%
Previous 0.23%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$163.84 - $199.33 $14,417 - $17,541
88 Added 5.13%
1,804 $356,000
Q2 2024

Jul 24, 2024

BUY
$154.79 - $180.76 $47,056 - $54,951
304 Added 21.53%
1,716 $294,000
Q1 2024

May 15, 2024

BUY
$159.82 - $182.1 $7,511 - $8,558
47 Added 3.44%
1,412 $257,000
Q4 2023

Feb 06, 2024

BUY
$137.6 - $154.97 $187,824 - $211,534
1,365 New
1,365 $211,000
Q3 2022

Oct 14, 2022

BUY
$134.21 - $153.93 $116,225 - $133,303
866 New
866 $116,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Edge Rock Capital LLC Portfolio

Follow Edge Rock Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Edge Rock Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Edge Rock Capital LLC with notifications on news.